{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"8b15f6df-c45d-4575-89cb-441c5de831bd","name":"Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy","doi":"10.17605/OSF.IO/ZWUEK","doi_status":"minted","osf_url":"https://osf.io/zwuek/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_77b3b54dad4f4b45/chain","content_hash":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe","provenance_passport":{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","submission_id":"0f2f9765-1ad9-4a6a-bdcf-9a2bbcfba23c","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe","persistent_identifiers":{"doi":"10.17605/OSF.IO/ZWUEK","osf_url":"https://osf.io/zwuek/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_77b3b54dad4f4b45","dw_chain_url":"https://provenance.researka.org/artifacts/claim_77b3b54dad4f4b45/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"8b15f6df-c45d-4575-89cb-441c5de831bd","object_type":"publication","parent_object_id":"0f2f9765-1ad9-4a6a-bdcf-9a2bbcfba23c","title":"Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy","body_markdown":"# Alpha memo — acarbose\n\n**Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy\n**Confidence:** `evidence_backed_signal`\n**Memo surface:** `alpha memo`\n**Snapshot:** `2026-05-27T09-58-52Z`\n**Run:** `acarbose-evidence-2026-05-27T09-58-52Z`\n**Direct source breadth:** `5` direct cited source(s)\n**Source breadth:** `5/5` unique cited source(s)\n\n## One-sentence thesis\n\nThe cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering.\n\nKnown / obvious (do not republish): Acarbose is an alpha-glucosidase inhibitor used to lower postprandial blood glucose in type 2 diabetes.; Acarbose improves glycemic control by delaying carbohydrate absorption in the intestine.\n\nReal tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12).\n\n## Evidence receipts\n\n- `fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621\n- `fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621\n- `fact_id=187298` (`A_core`) — 0.918 (0.845-0.998) for every 1-year increment of cumulative duration of acarbose therapy doi=10.14336/ad.2019.0621\n- `fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90\n- `fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170\n- `fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013\n- `fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898\n\n## What this changes\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._\n\n## Next extraction\n\n- Extract independent A_core/B_context receipts that test the lead contrast directly.\n- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.\n\n## Provenance / priority\n\n- **Topic:** `acarbose`\n- **Author:** Dom Lynch\n- **ORCID:** _not configured_\n- **Version:** 1.0\n- **License:** CC BY-NC 4.0\n- **Canonical URL:** _not assigned_\n- **Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.\n- **Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`\n- **Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`\n- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.\n","metadata":{"abstract":"Alpha memo — acarbose","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":0,"primary_like_count":5,"year_start":2012,"year_end":2020},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","doi":"10.17605/OSF.IO/ZWUEK","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"zwuek","osf_url":"https://osf.io/zwuek/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"zwuek","url":"https://osf.io/zwuek/","doi":"10.17605/OSF.IO/ZWUEK"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_77b3b54dad4f4b45","dw_chain_url":"https://provenance.researka.org/artifacts/claim_77b3b54dad4f4b45/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_77b3b54dad4f4b45/chain","dw_source_artifact_id":"source_64d901974dea41c3","dw_input_artifact_ids":["source_3802f09507f5469b","source_c0e135cd3129475d","source_9852ca3314d0419b","source_af240262d65e4aa2","source_721466adbaed4e76","source_e2486c4cd6da4c18"],"dw_step_id":"step_ef2cd92c2a1a41d2","dw_step_hash":"c32fae46ee32824bb3d59c4b39272ef013de3e4b2b671499f8e9ad13066ad334","dw_status":"registered","content_hash":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe","sha256":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe"},"created_at":"2026-05-27T16:10:52.673747+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","traces":[{"claim_id":"claim_1","claim":"Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_2","claim":"The cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_3","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_4","claim":"The discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering.","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_5","claim":"Real tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12).","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_6","claim":"`fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_7","claim":"`fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_8","claim":"`fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_9","claim":"`fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_10","claim":"`fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_11","claim":"`fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_12","claim":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_13","claim":"Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]},{"claim_id":"claim_14","claim":"Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.","candidate_sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","url":null},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","url":null},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","url":null},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","url":null},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","content_hash":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe","nodes":[{"id":"8b15f6df-c45d-4575-89cb-441c5de831bd","type":"publication","title":"Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy"},{"id":"claim_1","type":"claim","text":"Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy"},{"id":"claim_2","type":"claim","text":"The cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_3","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_4","type":"claim","text":"The discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering."},{"id":"claim_5","type":"claim","text":"Real tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12)."},{"id":"claim_6","type":"claim","text":"`fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621"},{"id":"claim_7","type":"claim","text":"`fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621"},{"id":"claim_8","type":"claim","text":"`fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90"},{"id":"claim_9","type":"claim","text":"`fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170"},{"id":"claim_10","type":"claim","text":"`fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013"},{"id":"claim_11","type":"claim","text":"`fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898"},{"id":"claim_12","type":"claim","text":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._"},{"id":"claim_13","type":"claim","text":"Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0."},{"id":"claim_14","type":"claim","text":"Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version."},{"id":"source_1","type":"source","study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","year":2020,"doi":"10.14336/ad.2019.0621","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","year":2014,"doi":"10.3346/jkms.2014.29.1.90","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","year":2014,"doi":"10.1111/acel.12170","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","year":2012,"doi":"10.4236/jdm.2012.21013","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Acarbose improves health and lifespan in aging HET3 mice","year":2019,"doi":"10.1111/acel.12898","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"**Topic:** `acarbose`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_7","type":"source","study":"**Author:** Dom Lynch","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_8","type":"source","study":"**ORCID:** _not configured_","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_9","type":"source","study":"**Version:** 1.0","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_10","type":"source","study":"**License:** CC BY-NC 4.0","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_11","type":"source","study":"**Canonical URL:** _not assigned_","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_12","type":"source","study":"**Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_13","type":"source","study":"**Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_14","type":"source","study":"**Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_15","type":"source","study":"**Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_1","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_2","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_3","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_4","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_5","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_6","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_7","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_8","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_9","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_10","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_11","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_12","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_13","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_14","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Real tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12)."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nDementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEffect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAcarbose improves health and lifespan in aging HET3 mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n**Topic:** `acarbose`,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Author:** Dom Lynch,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**ORCID:** _not configured_,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Version:** 1.0,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**License:** CC BY-NC 4.0,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Canonical URL:** _not assigned_,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n\"**Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","doi":"10.14336/ad.2019.0621","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","doi":"10.3346/jkms.2014.29.1.90","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","doi":"10.1111/acel.12170","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","doi":"10.4236/jdm.2012.21013","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Acarbose improves health and lifespan in aging HET3 mice","doi":"10.1111/acel.12898","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"**Topic:** `acarbose`","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Author:** Dom Lynch","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**ORCID:** _not configured_","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Version:** 1.0","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**License:** CC BY-NC 4.0","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Canonical URL:** _not assigned_","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}}]}